AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
This article outlines typical volatile periods for SP 500 and how retirees can position portfolios to endure drawdowns while meeting needs.
26,423 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
A controversial proposal has sparked a fierce debate among developers, miners, and industry leaders. This article unp...
A top executive recently disclosed selling a sizable block of Qualys stock. This article explains how to interpret in...
A top Interface executive dumped stock in a move worth hundreds of thousands. Is this a signal about the business or ...
Triata Capital's sizable stake reduction in GDS Holdings has traders and investors buzzing about AI data-center expos...
SpaceX sits on a colossal cash hoard, but does $100 billion guarantee long-term growth? This guide breaks down what t...
Sam Altman raised questions about SpaceX's bold plan for AI data centers in space. This article breaks down the viabi...
SpaceX is rumored to pursue a summer IPO valued at about $1.5 trillion, a move that would reshape public market norms...
Investors eyes are on Hackett Group as 2026 unfolds. This guide breaks down how to read the Hackett Group (HCKT) 2026...
Hot IPOs spark excitement, but do they indicate a market top? This guide compares today’s IPO activity to past bubble...
A surprising gift disclosure involving a music label and a Supreme Court justice reveals the money-side of public tra...
When a high-ranking executive at a major company sells shares, it can spark questions about the stock’s outlook. This...